Skip to main content
RAPS Euro Convergence 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Ticketed Event
Ticketed Event
Sponsored Presentation
Sponsored Presentation
Learning Level: Foundational
Learning Level: Foundational
New Exhibitor
New Exhibitor
Networking Event
Networking Event
Enterprise Network Member
Enterprise Network Member
Learning Level: Expert
Learning Level: Expert
Learning Level: Advanced
Learning Level: Advanced
Learning Level: Intermediate
Learning Level: Intermediate
Back
Download Certificate ViewAttendees 13

AI/Software

Regulators and Industry Perspective on Use of Artificial Intelligence in the Drug Development Lifecycle

Tuesday, May 7, 2024
16:45 – 17:45 CEST
Location: B 07 + B 08
Learning Level: Intermediate
Description: Artificial Intelligence and Machine Learning tools have found their way to the forefront of drug development discussions and recently health authorities have joined in the conversation by either issuing guidances or creating forums to engage stakeholders on this topic. Some regulators have put out guidance or created forums to engage stakeholders on this topic. In this session, we will invite industry, health authority and technology stakeholders to discuss the key features and framework of use of Artificial Intelligence in Drug Development. We will also compare and contrast each regulatory agency's thinking on AI and what the real-world application may look like.

Learning Objectives:

  • Better understanding of the framework that regulators have put out regarding Artificial Intelligence in the Drug Development Lifecycle
  • Deep dive into similarities sand differences between various regulators and their regions
  • How to apply use of Artificial Intelligence in tangible use cases during drug development lifecycle